Phase II Study of Pemetrexed Monotherapy in Patients With Platinum-resistant Squamous Cell Carcinoma of Head and Neck
The treatment option in patients with platinum-resistant relapsed or metastatic squamous
cell carcinoma of head and neck is limited. Previous randomized phase III study showed a
borderline benefit of pemetrexed added to cisplatin. Therefore, we aim to evaluate the
efficacy of pemetrexed in salvage setting.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
6 weeks
No
Ye Guo, MD
Principal Investigator
Fudan University
China: Ethics Committee
HNTG 11-01
NCT01333696
April 2011
June 2013
Name | Location |
---|